ViRexx Medical Corp. (TSX: VIR) (AMEX: REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B and C and embolotherapy treatments for tumors, today announced that its wholly owned Irish subsidiary, ViRexx International Corp., has entered into a Licensing and Supply Agreement and a Securities Purchase Agreement with Defiante Farmaceutica, Lda., as well as a Manufacturing and Supply Agreement with Tecnogen S.C.p.A subsidiaries of Sigma-Tau of Rome, Italy, for the manufacturing, licensing and distribution of OvaRex® MAb to its remaining unlicensed European territories, which include the U.K., Ireland, France, Sweden, Finland and other countries. Pursuant to the agreements, Defiante’s and ViRexx’s existing European licensing partners will market and distribute the product throughout most of Europe and the Middle East. The Manufacturing and Supply Agreement is expected to be ratified by Tecnogen’s Board of Directors when they next meet in January 2007. After such ratification, Tecnogen will manufacture and supply OvaRex® MAb for all of ViRexx’s European licensing partners.
